非臨床試験のための制御エアロゾルの連続生産におけるキャピラリーエアロゾル発生器の使用

Executive Industry Relevance

The capillary aerosol generator (CAG) enables reproducible, continuous aerosol production for in vivo inhalation toxicology studies where consumer devices are impractical. It provides precise control over aerosol chemistry and particle size through adjustable liquid flow, heating temperature, and dilution air, supporting mechanistic de-risking in early respiratory toxicology assessment. This capability enhances predictive confidence in formulation screening and portfolio triage for inhaled therapeutics.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables controlled exposure to test compounds via aerosol to interrogate respiratory tract hypotheses and pathway engagement.
• Operational Value: Delivers consistent aerosol concentrations and particle size distributions across replicates, reducing variability in target engagement readouts.

Screening & Assay Development

• Scientific Value: Generates aerosols with defined nicotine, glycerol, and propylene glycol concentrations to establish dose-response relationships in pulmonary assays.
• Operational Value: Achieves high reproducibility (RSD <3.5%) for aerosol-collected mass and key constituents under fixed parameters, supporting assay standardization.

Translational & Preclinical Research

• Scientific Value: Facilitates scaling of aerosol exposure from bench to in vivo studies while maintaining physicochemical similarity to electronic cigarette emissions.
• Operational Value: Allows systematic adjustment of cooling and dilution airflow to optimize mass-median aerodynamic diameter for regional lung deposition studies.

Pipeline & Workflow Integration

The CAG fits within the discovery continuum from formulation screening to inhalation toxicology, enabling iterative refinement of liquid compositions based on aerosol output metrics.

• Discovery Biology: Supports hypothesis testing of aerosolized compounds on cellular targets by delivering quantifiable, reproducible doses.
• Screening: Provides assay-ready aerosol streams with tunable particle size and concentration for high-content pulmonary screening.
• Analytics: Delivers quantitative outputs including aerosol-collected mass, nicotine yield, and particle size distribution for comparative condition analysis.
• Translational Research: Bridges in vitro findings to in vivo inhalation studies through controlled aerosol generation that mimics device emissions.
• Enterprise Reuse: Serves as a reusable platform for testing diverse e-liquid or therapeutic formulations under standardized aerosolization conditions.

Operational & Enterprise Impact

• Scientific Value: Reduces mechanistic ambiguity in inhalation studies by enabling precise control over aerosol composition and particle size.
• Operational Value: Ensures reproducibility and scalability of aerosol generation for multi-lab or longitudinal toxicology programs.
• Strategic Value: Improves go/no-go decisions in inhaled therapeutic development by providing reliable exposure data early in the pipeline.
• Portfolio Impact: Enables risk-adjusted prioritization of formulations based on reproducible aerosol yield and deposition characteristics.

Implementation Considerations

• Requires expertise in aerosol science, thermal evaporation principles, and inhalation toxicology protocols.
• Needs precision instrumentation including peristaltic pumps, temperature controllers, flow meters, and filter-based sampling systems.
• Demands cross-team standardization of liquid formulation preparation, heating profiles, and airflow settings for consistent results.
• Involves adaptation considerations when extending to non-nicotine therapeutic aerosols or varying solvent systems.
• Limited by inability to assess device-specific issues such as overheating of electronic cigarette components, focusing instead on aerosol generation fidelity.

Biopharma FAQs